Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,289,910 papers from all fields of science
Search
Sign In
Create Free Account
evolocumab
Known as:
AMG 145
, AMG-145
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
1 ML evolocumab 140 MG/ML Auto-Injector [Repatha]
1 ML evolocumab 140 MG/ML Prefilled Syringe
1 ML evolocumab 140 MG/ML Prefilled Syringe [Repatha]
3.5 ML evolocumab 120 MG/ML Cartridge [Repatha]
Expand
Narrower (1)
Repatha
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Status of PCSK9 Monoclonal Antibodies in Australia.
D. Scherer
,
A. Nelson
,
+7 authors
G. Watts
Heart, Lung and Circulation
2019
Corpus ID: 159039818
2019
2019
PCSK9-lowering RNAi contender clears first phase III trial
Asher Mullard
Nature reviews. Drug discovery
2019
Corpus ID: 202834046
2019
2019
Atopic Dermatitis-Like Rash During Evolocumab Treatment of Familial Hypercholesterolemia.
N. Kanda
,
F. Okajima
Journal of Nippon Medical School = Nippon Ika…
2019
Corpus ID: 195879794
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that targets the low-density lipoprotein (LDL…
Expand
2018
2018
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer.
Efthymia Tsakiridou
,
E. Liberopoulos
,
Z. Giotaki
,
S. Tigas
Journal of Clinical Lipidology
2018
Corpus ID: 205619199
2017
2017
Impact of Additional Lipid-Lowering Therapy on New Ischemic Lesions of Diffusion-Weighted Imaging in Carotid Artery Stenting.
Takashi Mizobe
,
Mitsugu Nakamura
,
Y. Motooka
,
Noriaki Ashida
,
Masahiro Sugihara
Journal of Stroke & Cerebrovascular Diseases
2017
Corpus ID: 46776452
2017
2017
Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach
N. Scherer
,
Christiane Dings
,
M. Böhm
,
U. Laufs
,
T. Lehr
Journal of clinical pharmacology
2017
Corpus ID: 4030349
Alirocumab and evolocumab are 2 human monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9…
Expand
2017
2017
Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial
S. R. Shah
,
Mohd Faisal Uddin
,
+4 authors
S. A. Shah
Journal of Community Hospital Internal Medicine…
2017
Corpus ID: 34635395
Dear Sir,Proprotein convertase subtilisin-kexin type 9 (PCSK9) is a protease that binds to the extracellular compartment of the…
Expand
2015
2015
Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance
D. Blom
,
C. Djedjos
,
+4 authors
E. Roth
2015
Corpus ID: 116552458
Rationale: Vitamin E transport and steroidogenesis are closely associated with low-density lipoproteins (LDLs) metabolism, and…
Expand
2015
2015
PCSK9 inhibitors – past, present and future
Ž. Reiner
Expert Opinion on Drug Metabolism & Toxicology
2015
Corpus ID: 24901046
Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular disease (CVD) morbidity and mortality. Statins are…
Expand
2014
2014
Adverse health effects of marijuana use.
C. Collins
New England Journal of Medicine
2014
Corpus ID: 183194800
1. Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE